Advertisement
Screener

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Overview

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Overview

  • 29 Mar 2026: Period ending 27 Jun 2026; Estimate (m); Actual -0.03; Beat / miss (m).
  • 28 Dec 2025: Period ending 28 Mar 2026; Estimate (m); Actual -0.30; Beat / miss (m).
  • 29 Jun 2025: Period ending 27 Sept 2025; Estimate (m); Actual 1.10; Beat / miss (m).
  • 30 Mar 2025: Period ending 28 Jun 2025; Estimate (m); Actual 1.06; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$142.43$170.90$205.06$246.05$295.22$354.232025-11-062026-11-06$94.76$127.29$170.99$229.69$308.53$414.452021-11-082026-11-06$66.52$98.82$146.79$218.06$323.94$481.212016-11-072026-11-06$19.74$37.39$70.82$134.14$254.07$481.212006-11-062026-11-06$17.10$33.33$64.97$126.65$246.87$481.212000-06-232026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$337.36
Previous close
$295.96
Change
$41.40
Change (%)
13.99%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

CRL
+48.37%
S&P 500
(m)

1 year

CRL
+101.35%
S&P 500
(m)

3 years

CRL
+51.02%
S&P 500
(m)

5 years

CRL
-30.05%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

27 Jun 2026 ○ Estimate (m) ● Actual -0.03

-0.380.040.450.871.2829 Mar 2025: estimate (m); actual 0.5029 Mar 2025(m)28 Jun 2025: estimate (m); actual 1.0628 Jun 2025(m)27 Sept 2025: estimate (m); actual 1.1027 Sept 2025(m)28 Mar 2026: estimate (m); actual -0.3028 Mar 2026(m)27 Jun 2026: estimate (m); actual -0.0327 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
29 Mar 202627 Jun 2026(m)-0.03(m)(m)
28 Dec 202528 Mar 2026(m)-0.30(m)(m)
29 Jun 202527 Sept 2025(m)1.10(m)(m)
30 Mar 202528 Jun 2025(m)1.06(m)(m)
29 Dec 202429 Mar 2025(m)0.50(m)(m)

27 Dec 2025 ○ Estimate (m) ● Actual -2.91

-2.990.173.336.509.6625 Dec 2021: estimate (m); actual 7.6025 Dec 2021(m)31 Dec 2022: estimate (m); actual 9.4831 Dec 2022(m)30 Dec 2023: estimate (m); actual 9.2230 Dec 2023(m)28 Dec 2024: estimate (m); actual 0.2028 Dec 2024(m)27 Dec 2025: estimate (m); actual -2.9127 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
29 Dec 202427 Dec 2025(m)-2.91(m)(m)
31 Dec 202328 Dec 2024(m)0.20(m)(m)
1 Jan 202330 Dec 2023(m)9.22(m)(m)
26 Dec 202131 Dec 2022(m)9.48(m)(m)
27 Dec 202025 Dec 2021(m)7.60(m)(m)

Revenue vs. Earnings

USD

27 Jun 2026 ■ Revenue 1.00B ■ Earnings -0.00B — Profit margin -0.15%

-0.43B-28.8%0.10B-17.1%0.63B-5.3%1.16B6.4%27 Sept 2025: revenue 1.00B; earnings 0.05B; profit margin 5.42%27 Sept 202527 Dec 2025: revenue 0.99B*; earnings -0.28B*; profit margin -27.82%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-09-28 to 2025-12-27; USD.27 Dec 202528 Mar 2026: revenue 1.00B; earnings -0.01B; profit margin -1.49%28 Mar 202627 Jun 2026: revenue 1.00B; earnings -0.00B; profit margin -0.15%27 Jun 2026

27 Dec 2025 ■ Revenue 4.02B ■ Earnings -0.14B — Profit margin -3.59%

-0.66B-4.6%1.11B1.3%2.88B7.3%4.64B13.2%31 Dec 2022: revenue 3.98B; earnings 0.49B; profit margin 12.23%31 Dec 202230 Dec 2023: revenue 4.13B; earnings 0.47B; profit margin 11.49%30 Dec 202328 Dec 2024: revenue 4.05B; earnings 0.02B; profit margin 0.55%28 Dec 202427 Dec 2025: revenue 4.02B; earnings -0.14B; profit margin -3.59%27 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$337.36(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$337.36High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning CRL

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
19.70K
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
954.87K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
3.81%*
Total return · month
1.53%*
Total return · quarter
31.21%*
Total return · half year
85.95%*
Total return · year to date
48.37%*
Total return · 1 year
101.35%*
Total return · 3 years
51.02%*
Total return · 5 years
-30.05%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Overview

View more →

(m)

(m)

SEC CIK
1100682
Industry (SIC)
8731 Services-Commercial Physical & Biological Research
Country of operation
United States
Business address
251 BALLARDVALE ST, WILMINGTON, Massachusetts, 01887, United States
Fiscal year end
1227
Phone
781-222-6000

Similar stocks

Stock NameCountryMarket CapPE Ratio
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
INCYTE CORP (INCY)United States$24.855B13.14
Absci Corp (ABSI)United States$1.775B-14.92
OmniAb, Inc. (OABI)United States$0.698B-8.05
NRC HEALTH (NRC)United States$0.450B42.50
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
OneMedNet Corp (ONMD)$0.042B
iSpecimen Inc. (ISPC)United States$0.003B
FOXO TECHNOLOGIES INC. (FOXO)United States$0.000B-277.71